About Tyra Biosciences Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://tyra.bio/
Frequently Asked Questions
What is the 52-week range for TYRA?
The 52-week high is $40.65 and the 52-week low is $12.98.
What is the P/E ratio for TYRA?
The P/E ratio data is currently unavailable.
What is the dividend yield for TYRA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -46.39%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 5.41.
Analyst Recommendation Trends
Wall Street analyst consensus for TYRA over the last few months:
Latest TYRA News
Raymond James Updates Healthcare Top Picks for October
Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeutics, Tyra Biosciences, and Oscar Health.
Oppenheimer Reiterates Outperform on Tyra Biosciences, Lowers Price Target to $40
Oppenheimer analyst Mazahir Alimohamed reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and lowers the price target from $50 to $40.
HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $29
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Tyra Biosciences (NASDAQ:TYRA) with a Buy and lowers the price target from $30 to $29.
Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?
Tyra Biosciences, Inc. (NASDAQ:TYRA) reported initial Phase 2 SURF302 results on September 9 for dabogratinib, an investigational oral FGFR3 inhibitor. The study enrolled patients with FGFR3-altered low-grade, intermediate-risk non-muscle-invasive bladder cancer. At the August 31, 2026 cutoff, 14 participants receiving 60 mg once daily had received treatment and completed at least the three-month disease assessment, […]
Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets
Tyra Biosciences has seen its share price swing sharply around recent trial updates and capital plans, which puts a fresh spotlight on what investors are really paying for against its book value. With the stock resetting after mixed bladder cancer drug data and a sizeable equity offering, the question is how closely that current market price lines up with the assets on its balance sheet. Over the past year, Tyra Biosciences has gained about 105.7%, which raises the issue of whether that move...
Stock Market Today: S&P 500, Dow and Nasdaq Futures Fall as Brent Hovers Near $107 and FOMC Commences Two-Day Meeting— MSTR, CRWD, BMM in Focus (UPDATED)
U.S. stock futures declined on Tuesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices fell, following Monday's lower close.
Crude Oil Jumps 3%; Corning Shares Move Lower
U.S. stocks fell Monday as tech slid; Nvidia may invest $10B in Anthropic’s IPO. Oil rose 3%, while gold, silver and copper declined.
Elmet Group, Rum Group, Tyra Biosciences And Other Big Stocks Moving Higher On Monday
Nasdaq fell 1%, while Elmet surged 50.6% on $450M DoD funding plans; Rum, SailPoint, Tyra and cybersecurity stocks also rallied.
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the pricing of an underwritten offering of 9,079,000 shares of its common stock at a price of $22.03 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 9,078,529 shares of common stock at a purchase price of $22
Tyra Biosciences Prices Underwritten Offering Of 9,079,000 Shares And Warrants At $22.03 Per Unit
Underwritten offering of 9,079,000 shares of its common stock at a price of $22.03 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 9,078,529 shares of common stock
Tyra Biosciences Files Prospectus To Sell Mixed Securities Shelf Of Undisclosed Amount
Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may offer and sell the securities identified above from time to time in one or more offerings. This prospectus provides you with a general description of the
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC September 9, 2026 8:00 AM EDTCompany...
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC - Slideshow
2026-09-10. The following slide deck was published by Tyra Biosciences, Inc.
Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $53 Price Target
Wedbush analyst Robert Driscoll reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and maintains $53 price target.
Apple To $370? Here Are 10 Top Analyst Forecasts For Thursday
Analysts cut targets for AAPL, CHWY, COO, TYRA and CNM; raised DLR, DPZ, SIG, while ratings stayed unchanged.
HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Tyra Biosciences (NASDAQ:TYRA) with a Buy and lowers the price target from $45 to $30.
Tyra Plummets To 10-Month Low On Mixed Cancer Test; Why Analysts Are Upbeat
Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment.
Tyra disappoints investors with bladder cancer data
Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer.
Gapping stocks in Wednesday's session
The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data
Tyra Biosciences (NASDAQ:TYRA) shares dropped 30% on Wednesday after the biotechnology company released initial results from its Phase 2 SURF302 trial of dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer. At the 60 mg once-daily dose, dabogratinib produced a 79% overall response rate and a 64% complete response rate as the best overall response among patients with single and multiple marker lesions combined.
Tyra Biosciences Tanks As IR NMIBC Data Disappoints: I'm Firmly On The Sidelines
Tyra Biosciences' stock slid 20% after Phase 2 dabogratinib missed the 70% CR goal in IR NMIBC. Read the latest analysis on the TYRA stock here.
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF) stock
Why Is Tyra Biosciences Stock Sinking Wednesday?
Tyra Biosciences stock fell sharply as initial dabogratinib Phase 2 data showed a 57% complete response rate at 60 mg.
Top movers in Wednesday's pre-market session
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). The study provided clinical proof of concept for selective oral FGFR3 inhibit
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $22.9 million. InnovAge Holding (NASDAQ:INNV)
Tyra Biosciences to Present at the Cantor Global Healthcare Conference
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conference:
Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts
Tyra Biosciences (TYRA) downgraded to Hold ahead of phase 2 SURF302 data; review FGFR3-targeting SNAP platform, cash runway, and key catalystsâread now.
Which stocks are experiencing notable movement on Friday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout
Tyra is set to host a conference call on September 9 to discuss initial results from its Phase 2 study evaluating Dabogratinib in patients with intermediate-risk non-muscle invasive bladder cancer.
HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $45 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with a Buy and maintains $45 price target.
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on Wednesday, September 9, 2026 at 8:00 am ET to discuss initial clinical results from the SURF302 Phase 2 study evaluating oral dabogratinib for intermediate risk non-muscle invasive bladder cancer (IR NMIBC).
Tyra Biosciences To Discuss Initial Clinical Results From SURF302 Phase 2 Study Evaluating Oral Dabogratinib For IR NMIBC In Conference Call And Webcast On September 9
Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | Rueb Yuliya | +2,925 | $9.129 | $26,702 |
| 2026-09-15 | Harris Todd | +864 | $9.129 | $7,887 |
| 2026-09-15 | RA CAPITAL MANAGEMENT, L.P. | +9,078,529 | $22.029 | $199,990,915 |
| 2026-09-15 | Fuhrman Alan | +951 | $9.129 | $8,682 |
| 2026-09-09 | Verjee Rehan | +972 | $20.5784 | $20,002 |
| 2026-05-28 | Verjee Rehan | +13,160 | - | - |
| 2026-05-28 | Rothenberg Stephen Michael | +13,160 | - | - |
| 2026-05-28 | Simson Jake | +13,160 | - | - |
| 2026-05-28 | Moran Susan | +13,160 | - | - |
| 2026-05-28 | Gulfo Adele M. | +13,160 | - | - |
| 2026-05-28 | RA Capital Healthcare Fund LP | +13,160 | - | - |
| 2026-05-28 | MORE ROBERT J | +13,160 | - | - |
| 2026-05-05 | Warner Douglas J | +85,000 | - | - |
| 2026-05-05 | Warner Douglas J | +25,000 | - | - |
| 2026-05-05 | Rueb Yuliya | +28,000 | - | - |
| 2026-05-05 | Rueb Yuliya | +8,333 | - | - |
| 2026-05-05 | Ashar Bhavesh | +50,295 | - | - |
| 2026-05-05 | Ashar Bhavesh | +15,013 | - | - |
| 2026-05-05 | Harris Todd | +265,000 | - | - |
| 2026-05-05 | Harris Todd | +79,000 | - | - |
| 2026-05-05 | Fuhrman Alan | +67,000 | - | - |
| 2026-05-05 | Fuhrman Alan | +20,000 | - | - |
| 2026-04-16 | Dable Habib J | +44,400 | - | - |
| 2026-03-26 | KAPLAN GILLA | -53,172 | - | - |
| 2026-03-26 | KAPLAN GILLA | -53,172 | $37.7483 | $2,007,153 |
| 2026-03-26 | KAPLAN GILLA | -53,172 | $2.25 | $119,637 |
| 2026-03-25 | KAPLAN GILLA | -14,295 | - | - |
| 2026-03-25 | KAPLAN GILLA | -14,295 | $36.9714 | $528,506 |
| 2026-03-25 | KAPLAN GILLA | +14,295 | $2.25 | $32,164 |
| 2026-03-13 | Harris Todd | +1,463 | $9.129 | $13,356 |
| 2026-03-13 | Fuhrman Alan | +1,376 | $9.129 | $12,562 |
| 2026-02-12 | Bensen Daniel | -5,872 | $33.3666 | $195,929 |
| 2026-02-12 | Bensen Daniel | -2,128 | $31.5018 | $67,036 |
| 2026-01-12 | Bensen Daniel | -1,017 | $29.0808 | $29,575 |
| 2026-01-12 | Bensen Daniel | -6,983 | $28.442 | $198,610 |
| 2025-12-19 | MORE ROBERT J | -10,000 | $25 | $250,000 |
| 2025-12-12 | Bensen Daniel | -8,000 | $22.6449 | $181,159 |
| 2025-12-01 | Ashar Bhavesh | +300,000 | - | - |
| 2025-11-21 | MORE ROBERT J | -246,871 | $20.2536 | $5,000,026 |
| 2025-11-19 | Bensen Daniel | -49,956 | $16.3203 | $815,297 |
| 2025-11-18 | Bensen Daniel | -75,633 | $16.0727 | $1,215,627 |
| 2025-11-17 | Bensen Daniel | -1,500 | $17.0713 | $25,607 |
| 2025-11-17 | Bensen Daniel | -18,572 | $16.1098 | $299,191 |
| 2025-11-14 | Bensen Daniel | -110,228 | $16.0167 | $1,765,489 |
| 2025-11-13 | Bensen Daniel | -1,111 | $16.0036 | $17,780 |